Young R C, Mitchell R C, Brown T H, Ganellin C R, Griffiths R, Jones M, Rana K K, Saunders D, Smith I R, Sore N E
Smith Kline & French Research Ltd., Welwyn, Hertfordshire, England.
J Med Chem. 1988 Mar;31(3):656-71. doi: 10.1021/jm00398a028.
A rational approach to the design of centrally acting agents is presented, based initially upon a comparison of the physicochemical properties of three typical histamine H2 receptor antagonists which do not readily cross the blood-brain barrier with those of the three brain-penetrating drugs clonidine (6), mepyramine (7) and imipramine (8). A good correlation was found between the logarithms of the equilibrium brain/blood concentration ratios in the rat and the partition parameter, delta log P, defined as log P (1-octanol/water)-log P (cyclohexane/water), which suggests that brain penetration might be improved by reducing overall hydrogen-bonding ability. This model has been employed as a guide in the design of novel brain-penetrating H2 antagonists by the systematic structural modification of representatives of different structural types of H2 antagonists. Although marked increases in brain penetration amongst congeners of cimetidine (1), ranitidine (9), and tiotidine (10) were achieved, no compound was found with an acceptable combination of H2 antagonist activity (-log KB in the guinea pig atrium greater than 7.0) and brain penetration (steady-state brain/blood concentration ratio greater than 1.0). Conversely, structural modification of N-[[(piperidinyl-methyl)phenoxy]propy]acetamide (30) led to several potent, novel compounds which readily cross the blood-brain barrier. One of these, zolantidine (SK&F 95282, 41), whose -log KB is 7.46 and steady-state brain/blood ratio is 1.4, has been identified for use in studying histaminergic H2 receptor mechanisms in brain. Comparison of delta log P values with the logarithms of the brain/blood ratios for 20 structurally diverse compounds for which data became available confirms a highly significant correlation and supports the general validity of this model.
本文提出了一种设计中枢作用药物的合理方法,首先比较了三种不易穿过血脑屏障的典型组胺H2受体拮抗剂与三种可穿透血脑屏障的药物可乐定(6)、美吡拉敏(7)和丙咪嗪(8)的物理化学性质。发现大鼠脑中平衡脑/血浓度比的对数与分配参数δlog P之间存在良好的相关性,δlog P定义为log P(1-辛醇/水)-log P(环己烷/水),这表明通过降低整体氢键结合能力可能会改善脑穿透性。该模型已被用作通过对不同结构类型的H2拮抗剂代表进行系统结构修饰来设计新型可穿透血脑屏障的H2拮抗剂的指导。虽然西咪替丁(1)、雷尼替丁(9)和替莫替丁(10)的同系物在脑穿透性方面有显著提高,但未发现具有可接受的H2拮抗剂活性(豚鼠心房中-log KB大于7.0)和脑穿透性(稳态脑/血浓度比大于1.0)组合的化合物。相反,N-[[(哌啶基-甲基)苯氧基]丙基]乙酰胺(30)的结构修饰产生了几种易于穿过血脑屏障的强效新型化合物。其中一种佐兰替丁(SK&F 95282,41),其-log KB为7.46,稳态脑/血比为1.4,已被确定用于研究脑中组胺能H2受体机制。将δlog P值与20种结构多样且有可用数据的化合物的脑/血比的对数进行比较,证实了高度显著的相关性,并支持该模型的普遍有效性。